ATE277083T1 - Antikörper, die spezifisch für fullerene sind - Google Patents

Antikörper, die spezifisch für fullerene sind

Info

Publication number
ATE277083T1
ATE277083T1 AT00957880T AT00957880T ATE277083T1 AT E277083 T1 ATE277083 T1 AT E277083T1 AT 00957880 T AT00957880 T AT 00957880T AT 00957880 T AT00957880 T AT 00957880T AT E277083 T1 ATE277083 T1 AT E277083T1
Authority
AT
Austria
Prior art keywords
fullerene
monoclonal antibody
provides
mouse
hybridoma
Prior art date
Application number
AT00957880T
Other languages
English (en)
Inventor
Bernard F Erlanger
Bi-Xing Chen
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of ATE277083T1 publication Critical patent/ATE277083T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2430/00—Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
AT00957880T 1999-08-31 2000-08-29 Antikörper, die spezifisch für fullerene sind ATE277083T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/386,658 US6593137B1 (en) 1999-08-31 1999-08-31 Antibodies specific for fullerenes
PCT/US2000/023629 WO2001016155A1 (en) 1999-08-31 2000-08-29 Antibodies specific for fullerenes

Publications (1)

Publication Number Publication Date
ATE277083T1 true ATE277083T1 (de) 2004-10-15

Family

ID=23526511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957880T ATE277083T1 (de) 1999-08-31 2000-08-29 Antikörper, die spezifisch für fullerene sind

Country Status (8)

Country Link
US (1) US6593137B1 (de)
EP (1) EP1218396B1 (de)
JP (1) JP2003508035A (de)
AT (1) ATE277083T1 (de)
AU (1) AU6943800A (de)
CA (1) CA2383015A1 (de)
DE (1) DE60014124T2 (de)
WO (1) WO2001016155A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949660B2 (en) * 1995-10-26 2005-09-27 Seth Nanotechnology, Incorporated Chiral (1pyrrolino) fullerene derivatives
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
US20030148380A1 (en) * 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
AU2002354929A1 (en) * 2001-07-16 2003-03-03 The Trustees Of Columbia University In The City Of New York Antibodies specific for nanotubes and related methods and compositions
US7485279B2 (en) 2001-12-18 2009-02-03 Yale University Growth of nanostructures with controlled diameter
JP4137794B2 (ja) 2001-12-18 2008-08-20 イエール ユニバーシティー 単層壁カーボン・ナノチューブの制御された成長
TW200307563A (en) * 2002-02-14 2003-12-16 Sixty Inc C Use of BUCKYSOME or carbon nanotube for drug delivery
US20080193490A1 (en) * 2002-02-14 2008-08-14 Andreas Hirsch Use of Carbon Nanotube for Drug Delivery
US7758889B1 (en) * 2002-07-24 2010-07-20 Luna Innovations Incorporated Fullerenes in targeted therapies
US7304128B2 (en) 2002-06-04 2007-12-04 E.I. Du Pont De Nemours And Company Carbon nanotube binding peptides
WO2005078814A2 (en) 2003-12-11 2005-08-25 Yale University Growth of boron nanostructures with controlled diameter
AU2004299492B2 (en) * 2003-12-15 2011-03-24 Nano-C, Inc. Higher fullerenes useful as radical scavengers
WO2006065243A1 (en) * 2004-12-16 2006-06-22 Nano-C, Inc. Higher fullerenes useful as radical scavengers
JP4827489B2 (ja) * 2005-10-25 2011-11-30 学校法人 東洋大学 可視光発光体の調製方法
JP2009513798A (ja) * 2005-10-27 2009-04-02 クレムソン・ユニヴァーシティ 蛍光性の炭素ナノ粒子
JP2007145635A (ja) * 2005-11-25 2007-06-14 Joetsu Univ Of Education フラーレン誘導体
EP1800706A1 (de) 2005-12-22 2007-06-27 Unomedical A/S Kehlkopfmaske
WO2008109033A1 (en) * 2007-03-02 2008-09-12 Luna Innovations Incorporated Steroid derivatives of fullerenes
US20100196246A1 (en) * 2007-10-09 2010-08-05 Headwaters Technology Innovation, Llc Methods for mitigating agglomeration of carbon nanospheres using a crystallizing dispersant
US7960440B2 (en) * 2007-10-09 2011-06-14 Headwaters Technology Innovation Llc Highly dispersible carbon nanospheres in an organic solvent and methods for making same
DE102008043654A1 (de) 2008-11-11 2010-05-20 Leibniz-Institut Für Festkörper- Und Werkstoffforschung Dresden E.V. Diagnostisches und/oder therapeutisches Agens, Verfahren zu seiner Herstellung und Verwendung
JP5395012B2 (ja) * 2010-08-23 2014-01-22 信越化学工業株式会社 レジスト下層膜材料、レジスト下層膜形成方法、パターン形成方法、フラーレン誘導体

Also Published As

Publication number Publication date
US6593137B1 (en) 2003-07-15
EP1218396A4 (de) 2003-05-07
AU6943800A (en) 2001-03-26
CA2383015A1 (en) 2001-03-08
EP1218396A1 (de) 2002-07-03
EP1218396B1 (de) 2004-09-22
JP2003508035A (ja) 2003-03-04
DE60014124D1 (de) 2004-10-28
DE60014124T2 (de) 2005-10-06
WO2001016155A1 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
ATE277083T1 (de) Antikörper, die spezifisch für fullerene sind
Bonvin et al. De novo isolation of antibodies with pH-dependent binding properties
JP4964957B2 (ja) 抗薬物抗体アッセイ
IL149062A0 (en) Improved method for detecting acid resistant microorganisms in the stool
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
YU45501A (sh) Humana monoklonalna antitela za ctla-4
ATE440868T1 (de) Monoklonaler antikírper gegen ein prion protein und dessen verwendung zum nachweis von prionen
RU97100179A (ru) Моноклональное антитело против cd44v6
JP2020534830A5 (de)
CY1107858T1 (el) Ccr5 αντισωματα pa14
US9766251B2 (en) Anti-human IgG1 antibody
US20220056112A1 (en) MONOCLONAL ANTIBODIES AGAINST SARS-CoV-2 NUCLEOCAPSID PROTEIN AND USES THEREOF
Murphy et al. Enhancing recombinant antibody performance by optimally engineering its format
DK1092767T3 (da) Serinproteasespecifikke monoklonale antistoffer og anvendelse deraf
JP2006317220A5 (de)
EP2562185B1 (de) Antikörper gegen humanes TSH und canines TSH
CA2522645A1 (en) New monoclonal antibody capable of binding integrin alpha10beta1
CN111208307B (zh) 一种与参照分子具有相同或不同的靶蛋白结合的分子的筛选方法
CA3007018A1 (en) Cgrp antibodies and uses thereof
CN117607447A (zh) 筛选抗体的方法及其应用
Kramer et al. Antibodies for biosensors
CN112094345A (zh) 可应用于肿瘤细胞捕获的小鼠抗免疫球蛋白关联βCD79b的单克隆抗体
RU2023134705A (ru) Антиидиотипические антитела против антител к cd79b
JP2023539279A (ja) 抗体を産生するための方法
CN112279917A (zh) 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd138的单克隆抗体

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties